Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT
NCT ID: NCT06441669
Last Updated: 2024-06-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
60 participants
OBSERVATIONAL
2024-05-01
2026-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT
NCT06306989
Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS
NCT06021210
Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT
NCT06812598
The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant Recipients
NCT06639854
Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCT
NCT05914675
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
letermovir group
Patients will be given Letermovir with a recommended dose of 480 mg per day (or 240 mg per day in patients taking cyclosporine or according to clinical instructions) from +1 day to +100 days after UCBT.
Letermovir
Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Letermovir
Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients start letemovir prophylaxis within 0-28 days post UCBT.
Exclusion Criteria
* Patients recruited in a clinical study on an anti-CMV trial.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Anhui Provincial Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Xiaoyu Zhu, ph.D
Role: PRINCIPAL_INVESTIGATOR
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provicial Hospital)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anhui Provincial Hospital
Hefei, Anhui, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CBCMV001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.